NBIX icon

Neurocrine Biosciences

113.16 USD
-0.84
0.74%
At close Mar 28, 4:00 PM EDT
After hours
113.16
+0.00
0.00%
1 day
-0.74%
5 days
0.45%
1 month
-4.68%
3 months
-17.44%
6 months
-1.79%
Year to date
-17.92%
1 year
-17.95%
5 years
23.55%
10 years
172.48%
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 108 | Existing positions closed: 72

20% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]

19% more capital invested

Capital invested by funds: $10.8B [Q3] → $12.9B (+$2.03B) [Q4]

4% more funds holding

Funds holding: 564 [Q3] → 585 (+21) [Q4]

9% more call options, than puts

Call options by funds: $48M | Put options by funds: $44.2M

4% more repeat investments, than reductions

Existing positions increased: 213 | Existing positions reduced: 204

0.01% more ownership

Funds ownership: 93.2% [Q3] → 93.21% (+0.01%) [Q4]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$147
30%
upside
Avg. target
$166
47%
upside
High target
$185
63%
upside

9 analyst ratings

positive
89%
neutral
11%
negative
0%
JP Morgan
Anupam Rama
24% 1-year accuracy
15 / 62 met price target
63%upside
$184
Overweight
Maintained
26 Mar 2025
Morgan Stanley
Jeffrey Hung
37% 1-year accuracy
10 / 27 met price target
33%upside
$150
Overweight
Assumed
7 Mar 2025
HC Wainwright & Co.
Andrew Fein
31% 1-year accuracy
109 / 356 met price target
63%upside
$185
Buy
Reiterated
24 Feb 2025
Guggenheim
Yatin Suneja
25% 1-year accuracy
8 / 32 met price target
44%upside
$163
Buy
Maintained
10 Feb 2025
RBC Capital
Brian Abrahams
17% 1-year accuracy
12 / 69 met price target
31%upside
$148
Sector Perform
Maintained
7 Feb 2025

Financial journalist opinion

Based on 6 articles about NBIX published over the past 30 days

Positive
The Motley Fool
4 days ago
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Explore the exciting world of Neurocrine Biosciences (NBIX -1.47%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Neutral
PRNewsWire
1 week ago
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO , March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Neutral
24/7 Wall Street
1 week ago
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
If you work in the biotech industry, you might know the name Alex Denner.
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Neutral
PRNewsWire
1 week ago
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider Symposium SAN DIEGO , March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA® (valbenazine) capsules in adults with Huntington's disease. The post-hoc analysis was presented at the Neuroscience Advanced Practice Provider Symposium hosted by the American Association of Neuroscience Nurses in New Orleans.
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
Neutral
PRNewsWire
2 weeks ago
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
SAN DIEGO , March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025.
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
Neutral
PRNewsWire
3 weeks ago
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
SAN DIEGO , March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an investigational, oral, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2 (VMAT2) in development for the potential treatment of certain neurological and neuropsychiatric conditions.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neutral
PRNewsWire
1 month ago
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
SAN DIEGO , Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD), irrespective of TD severity or underlying psychiatric condition. KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale used to evaluate the physical, social and emotional impact of involuntary movements.
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
Neutral
PRNewsWire
1 month ago
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston.
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neutral
PRNewsWire
1 month ago
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Neutral
The Motley Fool
1 month ago
Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NBIX -3.11%) hasn't been wowing analysts lately. On Monday, no less than three of them lowered their price targets on the biotech's shares, leaving them with a more than 3% loss in price on the day.
Why Neurocrine Biosciences Stock Sank Today
Charts implemented using Lightweight Charts™